Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, opened its first, state-of-the-art manufacturing facility in Brisbane, Queensland. The 60,000 sq.-ft. Vaxxas Biomedical Facility will serve as the company’s global headquarters and support the scale-up of its operations to produce HD-MAP vaccines for future late-stage clinical trials and first commercial products. The Queensland Government provided funding and operational support to Vaxxas ...